Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To see if teledermatology can be used to reduce antibiotic burden in patients on doxycycline or minocycline for acne vulgaris
The investigators are going to ascertain if antibiotic burden can be reduced with tele dermatology use.
There are two arms of the study:
All subjects will be randomised to either group, all subjects will take photos of their face and answer questions at baseline, visit 2 (1 month), visit 3 (2 months), visit 4 (3 months).
The investigators will then use measurements of acne grading (patient grading, investigator global assessment, lesion counting, global acne grading) to reduce/taper antibiotics in the feedback group.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non Feedback | Placebo Comparator | No feedback given to this group regarding their antibiotic use Subjects take images and answer questions during the study like the feedback group, but in this group no feedback re dosing is given. |
|
| Feedback group | Active Comparator | Feedback given to this group regarding their antibiotic use after baseline. If the subject is in the feedback group, after this visit, a dermatologist will review all images and the survey results and give the patient information about whether they should:
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Feedback group | Other | Monitoring ability to use teledermatology to modify antibiotic burden |
|
| Measure | Description | Time Frame |
|---|---|---|
| Reduced antibiotic use | The difference in antibiotic exposure in the physician feedback group compared to those not receiving feedback | Assessed at 4, 8, 12 weeks |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in acne grading (change in patient grading) | Change in Patient Grading | Assessed at 4, 8, 12 weeks |
| Change in acne grading (investigator global assessment) | Change in Investigator Global Assessment |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Raja Sivamani, MD | UC Davis | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UC Davis Department of Dermatology, Clinical Trials Unit | Sacramento | California | 95816 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000152 | Acne Vulgaris |
| ID | Term |
|---|---|
| D017486 | Acneiform Eruptions |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012625 | Sebaceous Gland Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Non Feedback group | Other | To use as control to see if antibiotic burden has been reduced in the active feedback group |
|
| Assessed at 4, 8, 12 weeks |
| Change in acne grading (lesion counting) | Change in Lesion Counting | Assessed at 4, 8, 12 weeks |
| Change in acne grading using the global acne grading | Change in Global Acne Grading | Assessed at 4, 8, 12 weeks |